The IRX1-NME1 axis modulates de novo fatty acid synthesis and breast cancer progression by targeting ACACA. In conclusion, our findings reveal that the IRX1- NME1/ACACA axis plays a critical role in de novo fatty acid synthesis and breast cancer progression, providing new insights into gene regulatory interactions and highlighting its potential as a novel therapeutic target for breast cancer.

Dynamic changes in serum VEGF levels were associated with treatment response; however, these findings should be interpreted with caution due to the retrospective design and absence of a control group. Further well-designed prospective controlled studies are warranted to validate these observations.

P2, N=1, Terminated, University of Missouri-Columbia | N=90 --> 1 | Trial completion date: Feb 2027 --> Apr 2026 | Enrolling by invitation --> Terminated | Trial primary completion date: Aug 2026 --> Apr 2026; Unable to find a sufficient number of suitable study patients.

P3, N=22220, Completed, Brigham and Women's Hospital | Active, not recruiting --> Completed | Phase classification: PN/A --> P3

Our drug screening assay showed that the fatty acid synthase (FASN) inhibitor cerulenin demonstrates strong and selective antiproliferative properties against NF2/CDKN2A(p16)-deficient PM cells, surpassing the effects of C75, cisplatin or pemetrexed. These findings suggest that FASN might play a role in the tumorigenesis of PM cells through the regulation of mitochondrial dynamics. This research offers a novel perspective on the potential development of precision medicine for PM.

Myocardial ischemia-reperfusion injury (MIRI) causes severe clinical complications in patients. Further analysis showed that GEM administration prevented the I/R-induced decrease in phospho-AMPK levels in ischemic cardiac tissue, and pharmacological inhibition of AMPK with dorsomorphin (DSMF) abolished all cardioprotective effects of GEM. Taken together, these results suggest that GEM mitigates MIRI-induced cardiac injury by inhibiting apoptosis and oxidative stress via modulation of AMPK, supporting its potential for reducing MIRI-related cardiac damage.

The objective response rate (ORR) was significantly increased by Kanglaite injection (RR = 1.52, 95% confidence interval [CI]: 1.07-2.15, p = 0.02)...Due to limitations in the assessed research, high-quality clinical studies with rigorous designs are required to confirm the findings. https://www.crd.york.ac.uk/PROSPERO/view/CRD42024561845, Identifier CRD42024561845.

Our study reveals a distinct lipid signature in gastric metaplasia characterized by TG and LD accumulation, providing novel therapeutic insights into targeting lipid metabolism to prevent GIM malignant transformation and reduce cancer risk.

Kanglaite injection (KLT) combined with CCRT (SUCRA: 85.1%; 90.1%) was optimal for enhancing performance status and one-year survival rate...Nevertheless, the findings shall be validated in multicenter, better-designed RCTs. The PRISMA registration details for this study can be found at: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024574242.

Kanglaite Injection (KLT) combined with chemotherapy had the best effect on reducing tumor markers CEA and CA153. Although a 2021 network meta-analysis (Comparative Efficacy and Safety of Chinese Herbal Injections Combined With Cyclophosphamide and 5-Fluorouracil Chemotherapies in Treatment of Breast Cancer: A Bayesian Network Meta-Analysis) examined chemotherapy combined with Chinese medicine injections for breast cancer, it was limited to the CF regimen and assessed few outcomes, with some lower-quality studies included (excluded herein)...This provides more comprehensive results, identifying SQFZ as most effective for improving response rate and Karnofsky Performance Status (KPS), thereby enhancing clinical utility. https://www.crd.york.ac.uk/PROSPERO/myprospero, identifier [CRD42024589306].

P2, N=90, Enrolling by invitation, University of Missouri-Columbia | Not yet recruiting --> Enrolling by invitation

P2, N=19, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Jun 2025 --> Mar 2025